Johan Wäborg
CEO since 2020. Employed since 2020. Born 1977.
Background: Over 17 years’ of experience within commercial management, commercial development, new company establishment and business partnership roles in the pharmaceutical industry across multiple geographies including Nordics, Europe, Russia, Latin America, Middle East, Northern Africa.
Education: MSc, Chemical engineering, The faculty of engineering at Lund University (LTH) and ETH Zurich.
Other assignments: Board member and owner, Phigalia AB.
Previous assignments in the past five years: General Manager at Actelion Pharmaceuticals Sverige AB (Stockholm, Sweden). General Manager at Marklas BV (Woerden, Netherlands). Regional Director Business Support at Actelion Ltd (Basel, Switzerland). Actelion listed at SIX Swiss Exchange.
Holding: 46,336 shares
Orest Lastow
CTO and Founder since 2020. Employed since 2014. Born 1964.
Background: Over 30 years’ experience inhalation development, mainly from AstraZeneca. Invented more than nine different inhaler devices and been involved in
the development of 13 different inhaler devices. More than 40 patent applications and has published several research articles and books. Also co-authored the ISO standard for inhaler devices and is a frequently invited speaker at inhalation conferences. Founder of Iconovo and CEO 2014-2020.
Education: MSc, Engineering Physics, Lund University. PhD, Aerosol Physics, Brunel University, London.
Other assignments: Board member, Lastow Consulting AB and Torna Hällestad Fastighets AB.
Previous assignments in the past five years: Board member, XO Sweden Wines & Spirits AB.
Holding: 826,400 shares
Mikael Arinder
Vice President Operations since 2016. Employed since 2016. Born 1964.
Background: Over 8 years’ experience of developing inhaler devices, mainly from AstraZeneca. Formerly project manager for large pharmaceutical and medical device projects at AstraZeneca.
Education: PhD, Organic Chemistry, Lund University.
Other assignments: -
Previous assignments in the past five years:
Holding: 3,500 shares
Mikael Ekström
Vice President Development since 2018. Born 1959.
Background: 30 years’ experience of pharmaceutical develop-ment at AstraZeneca, predominantly in inhala-tion, from the preclinical phase to Life Cycle Management.
Education: PhD, Organic Chemistry, Lund University.
Other assignments: -
Previous assignments in the past five years: Head of Inhalation Pharma Unit at Astra-Zeneca in Gothenburg consisting of Device, Formulation and Analyti-cal Development.
Holding: 381
Roger Lassing
Vice President Business Development since 2019. Born 1965.
Background: Over 25 years’ experience of business development, marketing, sales and analysis from the pharmaceutical industry. Involved in more than 30 pharmaceutical transactions. Previous roles include VP in Business Development, Global Brand Manager for Symbicort at AstraZeneca, and Market Analyst at Astra Draco. Also worked three years at McKinsey & Co in the health care sector in Brussels.
Education: BSc in Business Administration and Economics, Lund University.
Other assignments: -
Previous assignments in the past five years: Senior Manager Global Business Development LEO Pharma.
Holding: 11,300 shares
Peter Åkerlund
CFO since 2022. Born 1961.
Background: More than 35 years’ experience in accounting- and financial management,
corporate venture, strategy and business development.
Education: BSc in Business Administration, Lund University.
Other assignments: CFO SiB Solutions AB, owner and board member of Peter Åkerlund Consulting AB.
Previous assignments in the past five years: CFO IKEA GreenTech AB, CFO Gasporox AB (listed on Nasdaq First North), Head of Site Control Perstorp Specialty Chemicals AB, CFO Enjay AB
Holding: -